The price of Castle Biosciences Inc. (NASDAQ:CSTL) shares last traded on Wall Street fell -2.27% to $19.84.
Based on available information, 8 analysts follow Castle Biosciences Inc. (NASDAQ:CSTL). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $40.00 and a low of $25.00, we find $35.00. Given the previous closing price of $20.30, this indicates a potential upside of 72.41 percent. CSTL stock price is now 4.37% away from the 50-day moving average and -12.22% away from the 200-day moving average. The market capitalization of the company currently stands at $346.41M.
Among analysts, 0 rate the stock a hold while 7 rate it a buy. Brokers who have rated the stock have averaged $34.25 as their price target over the next twelve months.
With the price target of $54, Scotiabank recently initiated with Sector Outperform rating for Castle Biosciences Inc. (NASDAQ: CSTL).
In other news, Goldberg Ellen, Director bought 4,800 shares of the company’s stock on Jun 05. The stock was bought for $69,004 at an average price of $14.38. Upon completion of the transaction, the Director now directly owns 9,065 shares in the company, valued at $0.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16, Pres. & Chief Exec. Officer MAETZOLD DEREK J sold 2,506 shares of the business’s stock. A total of $57,187 was realized by selling the stock at an average price of $22.82. This leaves the insider owning 19,515 shares of the company worth $0.39 million. Insiders disposed of 356,453 shares of company stock worth roughly $7.07 million over the past 1 year. A total of 1.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CSTL stock. A new stake in Castle Biosciences Inc. shares was purchased by CAPTRUST FINANCIAL ADVISORS during the first quarter worth $3,348,000. NORGES BANK invested $2,603,000 in shares of CSTL during the first quarter. In the first quarter, SEI INVESTMENTS CO acquired a new stake in Castle Biosciences Inc. valued at approximately $1,911,000. INVENOMIC CAPITAL MANAGEMENT LP acquired a new stake in CSTL for approximately $1,731,000. ORION PORTFOLIO SOLUTIONS, LLC purchased a new stake in CSTL valued at around $589,000 in the second quarter. In total, there are 230 active investors with 84.60% ownership of the company’s stock.
A candlestick chart of Castle Biosciences Inc. (NASDAQ: CSTL) showed a price of $20.42 on Monday morning. During the past 12 months, Castle Biosciences Inc. has had a low of $9.26 and a high of $36.10. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 9.00, and a quick ratio of 8.80. The fifty day moving average price for CSTL is $18.96 and a two-hundred day moving average price translates $22.57 for the stock.
The latest earnings results from Castle Biosciences Inc. (NASDAQ: CSTL) was released for Mar, 2023. The net profit margin was -47.10% and return on equity was -17.70% for CSTL. The company reported revenue of $42.04 million for the quarter, compared to $26.85 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 56.55 percent.
Castle Biosciences Inc.(CSTL) Company Profile
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
